Publicaciones en las que colabora con MIGUEL ÁNGEL LÓPEZ RUZ (24)

2022

  1. DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)

    Viruses, Vol. 14, Núm. 3

  2. Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV

    Viruses, Vol. 14, Núm. 12

2021

  1. Effectiveness of the quadrivalent hpv vaccine in preventing anal ≥ hsils in a spanish population of hiv+ msm aged > 26 years

    Viruses, Vol. 13, Núm. 2

  2. Risk factors for ≥high-grade anal intraepithelial lesions in MSM living with HIV and the response to topical and surgical treatments

    PLoS ONE, Vol. 16, Núm. 2 February

2019

  1. ART is key to clearing oncogenic HPV genotypes (HR-HPV) in anal mucosa of HIV-positive MSM

    PLoS ONE, Vol. 14, Núm. 10

2018

  1. 5. Antibacterianos

    Manejo práctico de los antimicrobianos en medicina (Avicam), pp. 27-110

  2. Effect of monotherapy with darunavir/ cobicistat on viral load and semen quality of HIV-1 patients

    PLoS ONE, Vol. 13, Núm. 4

2017

  1. 5. Antibacterianos

    Manejo práctico de los antimicrobianos en medicina (Avicam), pp. 27-102

  2. Modificaciones de la fibrosis hepática valorada mediante elastometría transitoria en pacientes con respuesta viral sostenida tras el tratamiento de la hepatitis C en pacientes monoinfectados (VHC) y coinfectados (VHC – VIH)

    Actualidad médica, Tomo 102, Núm. 800, pp. 18-22

  3. Risk factors for infection by oncogenic human papillomaviruses in HIV-positive MSM patients in the ART era (2010-2016)

    Medicine (United States), Vol. 96, Núm. 39

  4. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM)

    AIDS Research and Therapy, Vol. 14, Núm. 1

2016

  1. Effect of monotherapy with darunavir/ ritonavir on viral load in seminal fluid, and quality parameters of semen in HIV-1-Positive patients

    PLoS ONE, Vol. 11, Núm. 7

  2. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens

    PLoS ONE, Vol. 11, Núm. 2

2015

  1. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study

    HIV Medicine, Vol. 16, Núm. 10, pp. 628-634

2014

  1. Antiretroviral therapy as a factor protective against anal dysplasia in HIV-infected males who have sex with males

    PLoS ONE, Vol. 9, Núm. 3

2009

  1. Resistencias genotípicas en pacientes con VIH-1 y grados de viremia persistentemente bajos

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 27, Núm. 2, pp. 75-80

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

2006

  1. Endocarditis due to Mycoplasma hominis [2]

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 24, Núm. 7, pp. 470-471

  2. Impacto de los factores demográficos y psicosociales en la no adherencia a los fármacos antirretrovirales

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 24, Núm. 6, pp. 373-378

2005

  1. Clinical status, adherence to HAART and quality of life in HIV-infected patients receiving antiretroviral treatment

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 23, Núm. 10, pp. 581-585